Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00
暂无分享,去创建一个
R. Gelber | A. Goldhirsch | G. Pruneri | G. Viale | A. Vingiani | C. Criscitiello | G. Curigliano | M. Regan | T. Ruhstaller | K. Price | I. Láng | M. Colleoni | G. Cancello | E. Munzone | R. Kammler | K. Gray | L. Gianni